Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Matt E. Kalaycio, O. George Negrea, Steven L. Allen, Kanti R. Rai, Rashid M. Abbasi, Heather Horne, William A. Wegener & David M. Goldenberg. (2016) Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*. Leukemia & Lymphoma 57:4, pages 803-811.
Read now
Read now
Michael Doubek & Michal Šmída. (2015) Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?. Expert Review of Hematology 8:6, pages 743-764.
Read now
Read now
Piotr Smolewski & Tadeusz Robak. (2015) The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Drug Discovery 10:7, pages 791-808.
Read now
Read now
Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2015) Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 20:3, pages 423-447.
Read now
Read now
Tadeusz Robak. (2014) Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. Expert Review of Hematology 7:6, pages 841-857.
Read now
Read now
Catherine Rioufol & Gilles Salles. (2014) Obinutuzumab for chronic lymphocytic leukemia. Expert Review of Hematology 7:5, pages 533-543.
Read now
Read now
Divaya Bhutani & Ulka N Vaishampayan. (2013) Monoclonal antibodies in oncology therapeutics: present and future indications. Expert Opinion on Biological Therapy 13:2, pages 269-282.
Read now
Read now
Mark P Chao. (2013) Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies. Cancer Management and Research 5, pages 251-269.
Read now
Read now
Articles from other publishers (32)
Umesh Panwar, Mohammad Aqueel Khan, Chandrabose Selvaraj & Sanjeev Kumar Singh. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal
3
29
.
Emily M. Altman. (2020) Novel Therapies for Pemphigus Vulgaris. American Journal of Clinical Dermatology 21:6, pages 765-782.
Crossref
Crossref
Frank R. Brennan, Emma Smith & Sherri Dudal. 2019. Nijkamp and Parnham's Principles of Immunopharmacology. Nijkamp and Parnham's Principles of Immunopharmacology
369
406
.
Saskia Meyer, Mitchell Evers, Johannes H. M. Jansen, Jos Buijs, Blanca Broek, Stephanie E. Reitsma, Petra Moerer, Mojtaba Amini, Anna Kretschmer, Toine ten Broeke, Marcel T. den Hartog, Mark Rijke, Christian Klein, Thomas Valerius, Peter Boross & Jeanette H. W. Leusen. (2018) New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. British Journal of Haematology 180:6, pages 808-820.
Crossref
Crossref
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
Crossref
Tadeusz Robak, Jerzy Z. Blonski & Pawel Robak. (2016) Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. Seminars in Oncology 43:2, pages 280-290.
Crossref
Crossref
Subhashini Archana Kadavakolan, Sonam Puri, Sandeep Sahay & Jitesh Joshi. (2016) An update on newer monoclonal antibodies in lymphoma therapy. Asian Journal of Oncology 02, pages 003-007.
Crossref
Crossref
Sander W. Tas & Dominique L. P. Baeten. 2016. Suppression and Regulation of Immune Responses. Suppression and Regulation of Immune Responses
143
155
.
Joost P.M. Melis, Kristin Strumane, Sigrid R. Ruuls, Frank J. Beurskens, Janine Schuurman & Paul W.H.I. Parren. (2015) Complement in therapy and disease. Molecular Immunology 67:2, pages 117-130.
Crossref
Crossref
Steven M. Larson, Jorge A. Carrasquillo, Nai-Kong V. Cheung & Oliver W. Press. (2015) Radioimmunotherapy of human tumours. Nature Reviews Cancer 15:6, pages 347-360.
Crossref
Crossref
Serengulam V. Govindan, Thomas M. Cardillo, Edmund A. Rossi, Preeti Trisal, William J. McBride, Robert M. Sharkey & David M. Goldenberg. (2014) Improving the Therapeutic Index in Cancer Therapy by Using Antibody–Drug Conjugates Designed with a Moderately Cytotoxic Drug. Molecular Pharmaceutics 12:6, pages 1836-1847.
Crossref
Crossref
Stanley C Jordan, Jua Choi & Ashley Vo. (2015) Achieving incompatible transplantation through desensitization: current perspectives and future directions. Immunotherapy 7:4, pages 377-398.
Crossref
Crossref
KAZUNORI KATO. (2015) Therapeutic Monoclonal Antibodies for Cancer: The Past, Present, and Future. Juntendo Medical Journal 61:6, pages 601-607.
Crossref
Crossref
Frank R. Brennan. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1115
1126
.
Matthew Zibelman, Hossein Borghaei & Anthony J. Olszanski. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
787
822
.
Edmund A. Rossi, Chien-Hsing Chang & David M. Goldenberg. (2014) Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus. PLoS ONE 9:5, pages e98315.
Crossref
Crossref
Andrew Davies, Francesco Merli, Biljana Mihaljevic, Noppadol Siritanaratkul, Phillippe Solal-Céligny, Martin Barrett, Claude Berge, Beate Bittner, Axel Boehnke, Christine McIntyre & David MacDonald. (2014) Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. The Lancet Oncology 15:3, pages 343-352.
Crossref
Crossref
Howard A. Liebman, Mansoor N. Saleh, James B. Bussel, Ovidiu George Negrea, Heather Horne, William A. Wegener & David M. Goldenberg. (2013) Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. British Journal of Haematology 162:5, pages 693-701.
Crossref
Crossref
Serengulam V. Govindan, Thomas M. Cardillo, Robert M. Sharkey, Fatma Tat, David V. Gold & David M. Goldenberg. (2013) Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers. Molecular Cancer Therapeutics 12:6, pages 968-978.
Crossref
Crossref
Ernest H. Choy, Arthur F. Kavanaugh & Simon A. Jones. (2013) The problem of choice: current biologic agents and future prospects in RA. Nature Reviews Rheumatology 9:3, pages 154-163.
Crossref
Crossref
Nancy E. Everds & Jacqueline M. Tarrant. (2013) Unexpected Hematologic Effects of Biotherapeutics in Nonclinical Species and in Humans. Toxicologic Pathology 41:2, pages 280-302.
Crossref
Crossref
Tadeusz Robak. (2013) Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncology 9:1, pages 69-91.
Crossref
Crossref
Karen D. Price & Gautham K. Rao. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics
303
342
.
Tadeusz Robak. 2013. Non-Hodgkin Lymphoma. Non-Hodgkin Lymphoma
191
212
.
Shundong Cang, Nikhil Mukhi, Kemeng Wang & Delong Liu. (2012) Novel CD20 monoclonal antibodies for lymphoma therapy. Journal of Hematology & Oncology 5:1.
Crossref
Crossref
Janice M. Reichert & Eugen Dhimolea. (2012) The future of antibodies as cancer drugs. Drug Discovery Today 17:17-18, pages 954-963.
Crossref
Crossref
Peter J Bugelski & Pauline L Martin. (2012) Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. British Journal of Pharmacology 166:3, pages 823-846.
Crossref
Crossref
Lapo Alinari, Beth Christian & Robert A. Baiocchi. (2012) Novel targeted therapies for mantle cell lymphoma. Oncotarget 3:2, pages 203-211.
Crossref
Crossref
Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo & David M. Goldenberg. (2012) Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies. Molecular Cancer Therapeutics 11:1, pages 224-234.
Crossref
Crossref
Britt Nakken, Ludvig A. Munthe, Yrjö T. Konttinen, Anna Klokk Sandberg, Zoltan Szekanecz, Philip Alex & Peter Szodoray. (2011) B-cells and their targeting in rheumatoid arthritis — Current concepts and future perspectives. Autoimmunity Reviews 11:1, pages 28-34.
Crossref
Crossref
Robert M. Sharkey, Habibe Karacay, Serengulam V. Govindan & David M. Goldenberg. (2011) Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models. Molecular Cancer Therapeutics 10:6, pages 1072-1081.
Crossref
Crossref
Tadeusz Robak & Ewa Robak. (2011) New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies. BioDrugs 25:1, pages 13-25.
Crossref
Crossref